Improved W boson mass measurement with the D0 detector

We have measured the W boson mass using the D0 detector and a data sample of 82 pb^-1 from the Tevatron collider. This measurement used W -> e nu decays, where the electron is close to a boundary of a central electromagnetic calorimeter module. Such 'edge' electrons have not been used in any previous D0 analysis, and represent a 14% increase in the W boson sample size. For these electrons, new response and resolution parameters are determined, and revised backgrounds and underlying event energy flow measurements are made. When the current measurement is combined with previous D0 W boson mass measurements, we obtain M_W = 80.483 +/- 0.084 GeV. The 8% improvement from the previous D0 measurement is primarily due to the improved determination of the response parameters for non-edge electrons using the sample of Z bosons with non-edge and edge electrons.Comment: submitted to Phys. Rev. D; 20 pages, 18 figures, 9 table

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic. Funding: Bill & Melinda Gates Foundation

Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer. Methods: Patients included in the cohort were identified from a registry of patients treated through expanded access to nivolumab before and after Health Canada approval. Demographics were collected from the application forms. Outcome data for the duration of treatment and survival were collected retrospectively. Results: In contrast to the randomized clinical trial populations, our study cohort included patients who were older (median age: 66 years; range: 36–92 years) and who had an Eastern Cooperative Oncology Group performance status of 2 (8.9%). Despite the poorer-prognosis cohort, median overall survival was 12.0 months, which is comparable to the survival demonstrated in the randomized phase iii trials of nivolumab in lung cancer. Median time to treatment discontinuation was 3.45 months and was similar for all patient subgroups, including poorer-prognosis groups such as those with a performance status of 2, those 75 years of age and older, and those with brain metastases. Conclusions: Nivolumab given in a real-world clinical setting was associated with results similar to those reported in the phase iii clinical trial setting

Colour and decay resistance and its relationships in Eperua grandiflora

$\bullet$ Eperua grandiflora, which is widely distributed in the French Guiana forest region, shows high variability in decay resistance. Further information concerning this wood quality parameter is necessary, but standard testing methods are complex and time-consuming. We assessed the use of colorimetry to determine durability in heartwood samples from a range of trees. $\bullet$ Eperua grandiflora colour parameters were measured using a CIELAB system, revealing that the tree effect was greater than the radial position and height effects. $\bullet$ The wood samples were exposed to Coriolus versicolor and Antrodia sp. according to two European standards (En 350-1 and XP CEN TS 15083-1). Eperua grandiflora is more susceptible to brown rot. These two standards did not give the same durability classes. The high variation in natural durability was due to the tree effect. $\bullet$ These two properties were found to be correlated and the assessment also distinguished the extreme durability classes but they are not sufficient to classify the class of durability of this species.Étude de la variabilité de la couleur, de la durabilité naturelle et recherche de corrélations chez Eperua grandiflora. $\bullet$ Eperua grandiflora, essence largement répandue dans les forêts de Guyane soufre d'un défaut majeur : une grande variabilité de sa durabilité naturelle à l'égard des champignons lignivores. Dans un premier temps, nous avons étudié la variabilité de la mesure de la couleur selon le système CIElab afin de vérifier si la colorimétrie peut être utilisée comme un indicateur de la durabilité naturelle. $\bullet$ Nous avons étudié la résistance de cette essence à l'échelle inter, et intra-arbres à l'égard de Coriolus versicolor et Antrodia sp., conformément aux normes européennes en vigueur : EN 350-1 et XP TS 15083-1. Les résultats ont révélé qu'Eperua grandiflora est plus sensible au champignon de pourriture brune. $\bullet$ De même, l'utilisation des normes a montré que l'on n'obtenait pas les mêmes classes de durabilité. La variabilité de la durabilité et de la couleur est plus importante à l'échelle inter-arbres qu'à l'échelle intra-arbre. $\bullet$ Enfin, ces deux propriétés sont corrélées mais nous ne pouvons envisager d'utiliser la colorimétrie comme indicateur de la durabilité naturelle, car elle ne permet de différencier que les classes extrêmes